1-6 of 6
Bronte A. Jamison
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib

Clinical Trials & Observations
Wendy T. Parker, David T. O. Yeung, Alexandra L. Yeoman, Haley K. Altamura, Bronte A. Jamison, Chani R. Field, J. Graeme Hodgson, Stephanie Lustgarten, Victor M. Rivera, Timothy P. Hughes, Susan Branford
Journal: Blood
Blood (2016) 127 (15): 1870–1880.
https://doi.org/10.1182/blood-2015-09-666214
Published: 2016
Includes: Supplemental data
Journal Articles

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline

Clinical Trials & Observations
Susan Branford, David T. Yeung, Wendy T. Parker, Nicola D. Roberts, Leanne Purins, Jodi A. Braley, Haley K. Altamura, Alexandra L. Yeoman, Jasmina Georgievski, Bronte A. Jamison, Stuart Phillis, Zoe Donaldson, Mary Leong, Linda Fletcher, John F. Seymour, Andrew P. Grigg, David M. Ross, Timothy P. Hughes
Journal: Blood
Blood (2014) 124 (4): 511–518.
https://doi.org/10.1182/blood-2014-03-566323
Published: 2014
Includes: Supplemental data
Journal Articles

Additional BCR-ABL1 Mutations Identified By Sensitive Mass Spectrometry In Chronic Phase CML Patients With T315I Treated With Ponatinib Are Associated With Relatively Inferior Responses and Outcome

Wendy T Parker, PhD, Alexandra L Yeoman, BSc, Haley Altamura, BSc, Nicola Roberts, BSc, David T Yeung, BSc, MBBS, FRACP, FRCPA, Bronte A Jamison, BSc, Chani Field, BSc, Stephanie Lustgarten, PhD, Graeme Hodgson, PhD, Victor M. Rivera, PhD, Timothy P. Hughes, MD, MBBS, Susan Branford, PhD
Journal: Blood
Blood (2013) 122 (21): 651.
https://doi.org/10.1182/blood.V122.21.651.651
Published: 2013
Journal Articles

Early molecular response and female sex strongly predict stable undetectable BCR-ABL1 , the criteria for imatinib discontinuation in patients with CML

Clinical Trials & Observations
Susan Branford, David T. Yeung, David M. Ross, Jodi A. Prime, Chani R. Field, Haley K. Altamura, Alexandra L. Yeoman, Jasmina Georgievski, Bronte A. Jamison, Stuart Phillis, Brad Sullivan, Nancy E. Briggs, Mark Hertzberg, John F. Seymour, John Reynolds, Timothy P. Hughes
Journal: Blood
Blood (2013) 121 (19): 3818–3824.
https://doi.org/10.1182/blood-2012-10-462291
Published: 2013
Journal Articles

The patient's BCR-ABL1 Kinase Domain Mutation History Is Important for Decisions Regarding Tyrosine Kinase Inhibitor Therapy

Wendy T Parker, PhD, Alexandra L Yeoman, BSc, Bronte A Jamison, BSc, David T Yeung, BSc, MBBS, FRACP, FRCPA, Hamish S Scott, PhD, Timothy P Hughes, MD, Susan Branford, PhD
Journal: Blood
Blood (2012) 120 (21): 1692.
https://doi.org/10.1182/blood.V120.21.1692.1692
Published: 2012
Journal Articles

Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1 , a Criterion for Imatinib Discontinuation in Patients with CML

Susan Branford, PhD, David Ross, MBBS, PhD, Jodi Prime, BSc., Chani Field, BSc, Haley Altamura, BSc, Alexandra Yeoman, BSc, Jasmina Georgievski, BSc, Stuart Phillis, BSc, Bronte A Jamison, BSc, Brad Sullivan, BSc, David T Yeung, BSc, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS
Journal: Blood
Blood (2012) 120 (21): 165.
https://doi.org/10.1182/blood.V120.21.165.165
Published: 2012